semaglutide fda shortage list FDA's GLP-1 decision kicks off 'unprecedented' tussle over Hims: Is Tomorrow the End

2 Monotherapy is no longer available in the USA since Jan 2023, and lixisenatide-glargine (iGlarLixi) has been approved for type 2 diabetes

The FDA approved it in 2012 for chronic weight management in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as high blood pressure, type 2 diabetes, or high cholesterol

The best results come from doses of 2 g/day or more [6], especially if you have high LDL-C, high triglycerides, or extra weight [6]

3 Likes RapAdmin January 18, 2025, 6:23pm #64 Screen Shot 2025-01-18 at 10.21.57 AM1496862 95.9 KB Source: STAT 17 Jan 25 High-dose Wegovy leads to substantial weight loss in trial, but falls short

Oncogene (2006) 25(42):5787800.10.1038/sj.onc.1209576 8 ChenDLiuJRuiBGaoMZhaoNSunSet alGSTpi protects against angiotensin II-induced proliferation and migration of vascular smooth muscle cells by preventing signal transducer and activator of transcription 3 activation

Metabolic Stress Induces GD2 Expression and Cancer Stem Cell Phenotype in Triple Negative Breast Cancer